{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:05:53Z","timestamp":1779696353888,"version":"3.53.1"},"reference-count":16,"publisher":"Scientific Scholar","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>We proposed to administer Lu-177-DOTATATE in intra-arterial (IA) mode for higher first-pass localization to somatostatin receptors, higher residence time in liver metastases, and more radiation to tumor. This study aimed at assessing early hematological, renal and hepatotoxicity; and objective response to IA peptide receptor radionuclide therapy (PRRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Fourteen patients (4 females and 10 males) were prospectively assessed. 5\/14 patients underwent 2 cycles, whereas 3\/14 underwent 3 cycles, and 6\/14 received 1 cycle of IA PRRT. 200 mCi of Lu-177-DOTATATE was administered in 15\u201320 min by IA route under angiographic guidance. Patients were asked to follow-up at 4 and 8 weeks with hematological, liver, and renal functional parameters, and Ga-68 DOTATATE positron emission tomography\/computed tomography (PET\/CT) after 8 weeks. Response was assessed using RECIST 1.1 and EORTC PET criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Safety:<\/jats:italic>\n                      2\/14 patients had high total and direct bilirubin, which reverted to normal after IA PRRT. Three patients had low albumin, which improved after 1 cycle. Nine patients showed no worsening of liver function. Two patients showed Grade 1 hematotoxicity which reverted to normal. Five patients showed high creatinine, but preserved glomerular filtration rate and EC clearance. On follow-up at 8 weeks, serum creatinine reverted to normal.\n                      <jats:italic toggle=\"yes\">Efficacy:<\/jats:italic>\n                      In five patients who underwent 2 cycles of IA PRRT, 3 showed partial response (PR) on RECIST 1.1 and partial metabolic response (PMR) on EORTC criteria, whereas 2 showed stable disease (SD). In patients who underwent 3 cycles, 1 showed SD, whereas other patient showed PMR on DOTANOC PET\/CT, with PR in size. Among the remaining seven patients, 5 showed PMR, whereas the other 2 showed SD. Thus 9\/14 patients showed PR, whereas 5 showed SD on metabolic and size criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>IA PRRT is a safe and efficacious approach for the treatment of liver dominant metastatic neuroendocrine tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijnm.ijnm_7_23","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:04:16Z","timestamp":1716948256000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Intra-arterial PRRT with Lu-177 DOTATATE in Liver-dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and Toxicity"],"prefix":"10.25259","volume":"39","author":[{"given":"Ameya D","family":"Puranik","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin Sudhakar","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Gala","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Mohite","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar","family":"Marotkar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Gawale","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraja D","family":"Dev","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh V","family":"Shrikhande","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Chaudhari","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Bhandare","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archi","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilendu C","family":"Purandare","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchismita","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayak","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"R1-20240902","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"R2-20240902","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20240902","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate:Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-20240902","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"},{"key":"R5-20240902","first-page":"551","article-title":"Super-selective hepatic arterial infusions as established technique ('ARETAIEION'Protocol) of [177Lu] DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors","volume":"56","author":"Limouris","year":"2012","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R6-20240902","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MPA.0000000000000113","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors:The first US phase 2 experience","volume":"43","author":"Delpassand","year":"2014","journal-title":"Pancreas"},{"key":"R7-20240902","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term efficacy, survival, and safety of [(177) Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R8-20240902","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-015-3041-6","article-title":"Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine","volume":"42","author":"Sabet","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20240902","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20240902","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate:an analysis of the NETTER-1 study","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20240902","first-page":"179","article-title":"[(111)In-DTPA] octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration:An overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy","volume":"29","author":"Pool","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"R12-20240902","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/ERC-11-0144","article-title":"Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases","volume":"18","author":"Kratochwil","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"R13-20240902","doi-asserted-by":"crossref","first-page":"20210403","DOI":"10.1259\/bjr.20210403","article-title":"Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease","volume":"94","author":"Thakral","year":"2021","journal-title":"Br J Radiol"},{"key":"R14-20240902","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2016.11.170","article-title":"Contrast media use in patients with chronic kidney disease undergoing coronary angiography:A systematic review and meta-analysis of randomized trials","volume":"228","author":"Pandya","year":"2017","journal-title":"Int J Cardiol"},{"key":"R15-20240902","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","article-title":"Salvage PRRT with (177) Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET):Dosimetry, toxicity, efficacy, and survival","volume":"19","author":"Rudisile","year":"2019","journal-title":"BMC Cancer"},{"key":"R16-20240902","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13063-019-3888-0","article-title":"Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases:Study protocol for a multicenter, randomized controlled trial (LUTIA trial)","volume":"21","author":"Ebbers","year":"2020","journal-title":"Trials"}],"container-title":["Indian Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijnm.ijnm_7_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:38:10Z","timestamp":1779694690000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijnm.co.in\/intra-arterial-prrt-with-lu-177-dotatate-in-liver-dominant-metastatic-neuroendocrine-tumors-early-assessment-of-efficacy-and-toxicity\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijnm.ijnm_7_23","relation":{},"ISSN":["0972-3919","0974-0244"],"issn-type":[{"value":"0972-3919","type":"print"},{"value":"0974-0244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-01-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}